| Phase 15 trials · 1 met primary |
|
Phase 1
|
NCT07247396 |
Nov 2025 → May 2027 expected |
peritoneal carcinomatosis |
Second Affiliated Hospital, School of Medicine, Zhejiang University |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT07179692 |
Sep 2025 → Mar 2028 expected |
esophageal cancer, gastric cancer, lung cancer, malignant pancreatic neoplasm +1 |
Chongqing Precision Biotech Co., Ltd |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06126406 |
Nov 2023 → Dec 2025 overdue |
breast cancer, cholangiocarcinoma, colon carcinoma, esophageal cancer +4 |
Chongqing Precision Biotech Co., Ltd |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06043466 |
Aug 2023 → Dec 2026 expected |
bile duct cancer, breast cancer, colorectal cancer, esophageal cancer +3 |
Chongqing Precision Biotech Co., Ltd |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT05396300 |
May 2022 → Jun 2026 |
colorectal cancer, gastric cancer |
Weijia Fang, MD |
Completed
|
Met primary
|
| Phase 1/22 trials |
|
Phase 1/2
|
NCT06006390 |
Sep 2023 → Dec 2025 overdue |
breast cancer, colon carcinoma, esophageal cancer, gastric cancer +3 |
Chongqing Precision Biotech Co., Ltd |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT05538195 |
Jun 2022 → Dec 2023 |
esophageal cancer, gastric cancer, malignant pancreatic neoplasm, rectal cancer |
Chongqing Precision Biotech Co., Ltd |
Completed
|
No outcome recorded
|